LODOSYN (Carbidopa) Tablet [Bristol-Myers Squibb Pharma Company]
Updated Date: Sep 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial
Conclusions:
As monotherapy for early PD, pramipexole ER was noninferior to pramipexole IR and significantly more effective than placebo. Tolerability and safety did not differ between the formulations.
Classification of evidence:
This study provides Class I evidence that pramipexole ER is not inferior to pramipexole IR in patients with early PD. Neurologyreg; 2011;77:759ndash;766 (Source: Neurology)